ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag biotech clinical trials tuberculosis drug development

Tuberculosis Trial Launched
Hannah Waters | Mar 20, 2012 | 1 min read
The TB Alliance will test a new combination of drugs to combat normal and multi-drug-resistant tuberculosis.
How Vesselon Can Improve the Entire Class of Antibody-Drug Conjugates
Clayton Larsen - President & CEO, Vesselon, Inc. | Oct 30, 2023 | 4 min read
Vesselon’s novel co-formulation of gas lipid microspheres and self-assembling liposomes, targeted and activated by commercial ultrasound, would be an ideal adjunct to any of these ADC drugs.
A gloved hand holds a tweezer and pulls a section of DNA away from a double helix
First Person Dosed in Novel Gene Editing Clinical Trial
Amanda Heidt | Jul 12, 2022 | 4 min read
The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.
How Vesselon Can Improve the Entire Class of Radiopharmaceuticals
Clayton Larsen - President & CEO, Vesselon, Inc. | Nov 21, 2023 | 3 min read
Vesselon's microspheres optimize radiopharmaceuticals for targeted treatment, enhancing anti-tumor effects.
Oligonucleotide Therapeutics Near Approval
Catherine Offord | Dec 1, 2016 | 8 min read
Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Cannabis Biotech
Daniel Cossins | Dec 1, 2014 | 8 min read
As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.
Photograph of scientists working while wearing PPE
Contract Vivarium Facilities for Preclinical Discovery
The Scientist and Mispro | Mar 30, 2023 | 3 min read
Researchers rent contract vivarium space for greater experimental control, productivity, and reproducibility when developing new therapeutics.
A needle drawing up fluid from an unlabeled vial.
Cancer Vaccination as a Promising New Treatment Against Tumors
Shelby Bradford, PhD | Mar 15, 2024 | 10+ min read
Vaccination has beaten back infections for more than a century. Now, it may be the next big step in battling cancer.

Run a Search

ADVERTISEMENT